Skip to content

Topical continuous diffusion of oxygen combined with moist wound therapy for chronic wounds: A randomized controlled study

Topical continuous diffusion of oxygen combined with moist wound therapy for chronic wounds: A randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022167
Enrollment
Unknown
Registered
2019-03-27
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic wounds

Interventions

treatment group:topical continuous diffusion of oxygen combined with moist wound therapy
control group:Standard moist wound therapy

Sponsors

Wound Care Center of Outpatient Department, Eastern Theater General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged =18 years at the time of consent; (2) Wound that meets the definition chronic wound,including 3-4 pressury injury, Wagner 2-4 diabetic foot ulcer (Blood glucose control in the normal range, fasting blood glucose 3.9-6.1 mmol/L, 2 hours postprandial blood glucose = 7.8mmol/L), venous leg ulcer, surgical site infection,traumatic wound; (3) An index wound area measuring between 1.5–10cm2 after debridement at time of randomisation; (4) The quantity of exudate<15mL/d; (5) Subjects can follow the intervention and follow-up plan.

Exclusion criteria

Exclusion criteria: (1) Malignant wound; (2) Active bleeding wound; (3) Necrotic wounds covered with eschar or slough,but debridement is contraindicated or cannot be performed; (4) The wound edges are difficult to seal to create an occlusive environment; (5) Chronic wound secondary to infection requiring antibiotic treatment or being treated with antibiotics at the time of screening; (6) Systemic comorbidities that affect wound healing include autoimmune disease, malnutrition,advanced tumor,multiple organ failure, and unstable blood glucoseat the time of screening; (7) Receiving or has received steroids,immunosuppression, radiation or chemotherapy within three months of randomisation; (8) Subjects who have untreated osteomyelitis; (9) Enrolled or who have participated,within three months of randomisation,in another investigational device, drug or biological trial that may interfere with study results.

Design outcomes

Primary

MeasureTime frame
wound closed rate during the intervention period;

Secondary

MeasureTime frame
the percentage decrease in wound surface area,wound depth;bacterial species change;PUSH score;wound temperature;wound PH;MMP-9 expression;CD34 expression;Ki-67 expression;

Countries

China

Contacts

Public ContactJiang Qixia
jiangqixia1963@163.com+86 18900672707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026